Biology subjects

Newman, H.

Publications and source records attributed to Newman, H..

10 recordsLinked to original sources

bioRxiv2026

Hydrogel microneedle patch for low-cost, colorimetric, continuous glucose monitoring

Diabetes is a chronic condition characterized by dysregulated blood glucose levels. Continuous glucose monitors (CGMs) enable minimally invasive, real-time monitoring of glucose levels, but broader access requires devices that are both effective and affordable. Popular CGMs such as Dexcom and FreeStyle Libre have high accuracy and are integrated with mobile applications to display real-time data and alerts but are limited by high cost. We developed a low-cost, electronic-free, microneedle hydrogel patch CGM that utilizes colorimetric detection to continuously monitor glucose levels. The proposed patch penetrates the skin and absorbs interstitial fluid (ISF) containing glucose. This glucose reacts with glucose oxidase (GOx) enzyme embedded in the hydrogel, producing gluconic acid and decreasing the pH of the hydrogel. As glucose levels increase, decreasing pH levels are reported by the loaded pH indicator bromocresol purple (BCP) via a color change from purple to yellow. This system was validated through a combination of in vitro experiments and COMSOL computational modeling to assess performance at physiologically relevant glucose concentrations. The resulting hydrogels demonstrated reversible and dynamic color changes in response to glucose levels ranging from 3.5-10 mmol/L (63-180 mg/dL), supporting their potential for continuous monitoring applications. A quantitative, image-based analysis method enabled estimation of glucose concentration from photographs, demonstrating strong predictive performance (RMSE=8.59 mg/dL, R2=0.94). Although optimization of mechanical strength and diffusion kinetics remain necessary, these findings highlight the promise of integrating colorimetric sensing with microneedle-based sampling for affordable, user-friendly glucose monitoring.

bioengineering↗

bioRxiv2026

Engineered nanosponges mitigate peripheral stress-induced neuroinflammation and restore cognitive function

Systemic inflammation is increasingly recognized as a key driver of neuroinflammation and cognitive dysfunction, particularly in the aging population. Yet, therapeutic interventions that broadly attenuate circulating inflammatory mediators without suppressing host immunity remain limited. Here, we report the development of taurine functionalized hyaluronic acid nanosponges (HA Tau) that blunt systemic inflammatory cascades to protect against downstream neurocognitive impairment. Using molecular docking calculations and experimental validations, we show that taurine functionalization enhances multivalent interactions with diverse cytokines, enabling broad-spectrum sequestration of inflammatory proteins from both murine and human plasma while preserving the intrinsic hypochlorous acid neutralizing ability of taurine. In aged mice undergoing orthopedic surgery, systemic administration of HA Tau nanosponges lowered the levels of circulating inflammatory mediators, preserved blood brain barrier integrity, and attenuated glial cell activation. These effects were accompanied by improved hippocampal neuronal activity and spatial working memory in mice. By dampening peripheral inflammatory surges, the nanosponges limit peripheral-to-central inflammatory signaling without directly targeting the central nervous system. Collectively, these findings demonstrate systemic inflammatory modulation could be an effective strategy for mitigating peripheral insult-induced neuroinflammation and cognitive decline, and position HA Tau nanosponges as a versatile biomaterial platform for treating inflammation-driven disorders.

bioengineering↗

bioRxiv2026

Discovery, characterisation and optimisation of bicyclic peptide inhibitors that disarm Staphylococcus aureus a-hemolysin

-Hemolysin (Ahly) is a major Staphylococcus aureus virulence determinant implicated in tissue injury and immune dysregulation; antibody inhibitors have reached clinical trials but alternatives with improved ease of manufacture and tissue penetration are desirable. Here we demonstrate that phage-derived bicyclic peptides can serve as compact, chemically tractable Ahly neutralisers. Using TATB-scaffolded M13 phage libraries we identified WNP-motif containing bicyclic binders, with a lead hit of Peptide 14 (KD = 1792nM) and progressed the lead by iterative affinity maturation to Peptide 20 (KD = 609 nM) and by incorporation of strategically chosen non-canonical amino acids to yield Peptide 88 (KD = 96 nM). A 2.2 [A] co-crystal structure with AhlyH35A locates the binding footprint on the rim domain and explains the critical role of the WNP motif in target engagement. Functional assays show that the Peptide 88 blocks Ahly mediated hemolysis, inhibits Ahly driven ADAM10 activation, and elucidate its inhibitory mechanism of preventing Ahly binding to human A549 epithelial cells. Peptide 88 protects A549 cells from recombinant toxin and attenuates cytotoxicity in S. aureus co-culture experiments, whilst showing no toxicity to A549 cells. Bicyclic peptides thus represent a new and promising anti-virulence modality: small, synthetically accessible molecules that mimic antibody recognition, with therapeutic potential against S. aureus infections.

molecular biology↗

bioRxiv2025

Polysialic Acid Presentation on Microporous Scaffolds Supports Neural Repair after Ischemic Stroke

Recovery following ischemic stroke remains limited due to insufficient neural regeneration. Polysialic acid (PSA), a glycan prominently expressed during neural development, modulates neural progenitor cell (NPC) plasticity and migration, but its therapeutic potential in biomaterial-based stroke therapies remains underexplored. In this study, microporous annealed particle (MAP) scaffolds conjugated with PSA (PSA-MAP) were engineered to regulate NPC fate and promote neural tissue regeneration after stroke. PSA-MAP increased the presence of Sox2-positive progenitor cells within infarct and peri-infarct regions and elevated axonal content (NF200) in the lesion, while astrocytic and vascular coverage were not detectably changed at this early stage. In addition, 3D NPC cultures in MAP showed that tethered PSA alters NPC behavior over time, with reduced progenitor marker expression and PSA-dependent shifts in morphology, consistent with progression away from a progenitor state. Together, these data identify a glycan-forward, neuro-first repair route in which PSA-MAP enhances early neural regeneration without requiring concomitant angiogenic expansion, establishing PSA-MAP as a targeted biomaterial approach for endogenous neural repair after ischemic stroke.

bioengineering↗

bioRxiv2025

Polysialic Acid-Functionalized MAP Scaffolds Promote Regulatory Immune Responses After Ischemic Stroke

Glycosylation regulates immune and neural functions within the central nervous system (CNS), yet biomaterials rarely leverage glycans due to their structural complexity. Polysialic acid (PSA), comprising 2,8-linked sialic acid residues, is a promising candidate owing to its potent immunomodulatory interactions with inhibitory Siglec receptors. Systematic screening of multiple sialic acid derivatives identifies PSA as uniquely effective in inducing anti-inflammatory polarization of bone marrow-derived macrophages (BMDMs). Based on these findings, an injectable microporous annealed particle (MAP) scaffold presenting PSA covalently via its reducing end (MAP-PSA) is engineered, recapitulating physiological glycan orientation. MAP-PSA exhibits robust mechanical properties, stable glycan immobilization, and resistance to enzymatic degradation. Using ischemic stroke as a CNS injury model, MAP-PSA significantly reduces neutrophil infiltration and inflammatory activation while enhancing reparative macrophage and microglial phenotypes. These immunomodulatory effects persist into subacute stages, characterized by sustained reductions in inflammation and enhanced microglial homeostasis. Overall, MAP-PSA scaffolds demonstrate a novel therapeutic paradigm for CNS injuries such as stroke, with translational potential for broader neuroinflammatory and regenerative applications.

bioengineering↗

bioRxiv2025

Small siphophage binding to an open state of the LptDE outer membrane lipopolysaccharide translocon

Bacteriophages are bacterial viruses that provide alternatives to small-molecule drugs to combat infections by antibiotic-resistant bacteria. To infect a bacterial host, a phage needs to bind to the bacterial surface via receptor binding proteins (RBPs), which are critical for determining host specificity. For functionally important receptors, the RBP-receptor interaction could be exploited via phage steering, where emerging bacterial resistance due to receptor modification could make bacteria less fit or virulent. Despite this, relatively little is known about RBP-receptor interactions. Here we build on the recent discovery of coliphages that have the outer membrane (OM) lipopolysaccharide translocon LptDE as their terminal receptor and show via cryogenic electron microscopy (cryoEM) that, surprisingly, the RBP of the small siphophage Oekolampad binds to a hitherto unobserved, open state of LptDE. The open lateral gate of LptD is occupied by a {beta}-strand peptide originating from the degraded N-terminal jellyroll domain of LptD, suggesting the possibility of LptD inhibition via peptidomimetics. A structure of LptDE in complex with the superinfection exclusion (SE) protein Rtp45 of the Oekolampad-related phage Rtp shows a mechanism of SE where Rtp45-induced conformational changes in LptD resulting from steric clashes preclude RBP binding. Finally, analysis of spontaneous Oekolampad-resistant E. coli mutants identifies mutations in LptD that abolish the LptDE-RBP interaction in vitro. SDS-EDTA sensitivity assays of the mutants show no major defects in LptDE function, suggesting that phage steering via LptDE might be challenging. SignificanceThe outer membrane (OM) of Gram-negative bacteria is a protective barrier generated by lipopolysaccharide (LPS), a complex glycolipid that makes up the outer leaflet of the OM. Following its synthesis and transport from the inner membrane, LPS is inserted into the OM by LptDE, an OM protein complex essential for most Gram-negative bacteria. LPS insertion requires a hitherto unobserved, open state of LptDE. Here we report the unexpected finding that the receptor binding protein (RBP) of a bacteriophage binds to an open state of LptDE, allowing isolation and visualisation via cryogenic electron microscopy. The lateral gate of the LptDE-RBP complex is occupied by a {beta}-strand peptide, suggesting that the LptDE of pathogenic bacteria could be inhibited by peptidomimetics.

microbiology↗

bioRxiv2024

Discovery and chemical optimisation of a Potent, Bi-cyclic (Bicycle(R)) Antimicrobial Inhibitor of Escherichia coli PBP3

Penicillin binding proteins (PBPs) are well validated antimicrobial targets, but the prevalence of {beta}-lactamase driven resistance and, more rarely, target-based mutations, necessitates new classes of PBP-targeting drugs. Here we describe the discovery and optimisation of novel, bicyclic peptide (Bicycle(R)) inhibitors of E. coli PBP3 (EcPBP3) using a proprietary phage display platform, and their conjugation to linear antimicrobial peptides to confer outer membrane permeation. These molecules exhibited high-affinity binding to E. coli PBP3 and a viable spectrum of killing activity against clinically relevant species of the Enterobacterales. X-ray crystallography was used to explore the mode of binding to PBP3, enabling increased target affinity and improvement of in vitro stability. These compounds bind to the transpeptidase active site cleft of PBP3 and represent a novel non-{beta}-lactam chemical class of high affinity, non-covalent penicillin binding protein inhibitors.

biochemistry↗

bioRxiv2022

Targeting BET Proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML

Preclinical studies in myeloid neoplasms have demonstrated efficacy of Bromodomain and Extra-Terminal protein inhibitors (BETi). However, BETi demonstrate poor single agent activity in clinical trials. Several studies suggest that combination with other anti-cancer inhibitors may enhance the efficacy of BETi. To nominate BETi combination therapies for myeloid neoplasms, we used a chemical screen with therapies currently in clinical cancer development. We identified PIM inhibitors (PIMi) as therapeutically synergistic with BETi in myeloid leukemia models. Mechanistically, we show that PIM kinase is increased after BETi treatment, and that PIM kinase upregulation is sufficient to induce resistance to BETi and sensitize cells to PIMi. Further, we demonstrate that miR-33a downregulation is the underlying mechanism driving PIM1 upregulation. We also show that GM-CSF hypersensitivity, a hallmark of chronic myelomonocytic leukemia (CMML), represents a molecular signature for sensitivity to combination therapy and credential this using patient-derived xenografts supporting the clinical investigation of this combination.

cancer biology↗

bioRxiv2022

A multi-functional small molecule alleviates fracture pain and promotes bone healing

Skeletal injuries are a major cause of morbidities worldwide with bone fractures accounting for a substantial portion. Patients suffering from bone fractures and undergoing surgery experience different levels of pain throughout the healing process requiring pain-mitigating interventions. Furthermore, a considerable number of bone fractures suffer from delayed healing, and unresolved acute pain may transition to chronic and maladaptive pain. Current management of pain involves treatment with NSAIDs and opioids, however, these analgesics have substantial drawbacks including delaying healing, systemic side effects, and potential for addiction. Hence, a therapeutic approach that concomitantly attenuates pain locally and actively promotes healing would address a significant clinical problem and improve the overall functional outcome for patients. Herein, we tested the hypothesis that the purine molecule, adenosine, could simultaneously alleviate fracture pain and promote healing by targeting different adenosine receptor subtypes in different cell populations. Our results demonstrate that local delivery of adenosine inhibited nociceptive activity of peripheral neurons through activation of adenosine A1 receptor (ADORA1) and mitigates pain. Concurrently, localization of adenosine at the fracture site also promoted osteogenic differentiation of mesenchymal stromal cells through adenosine A2B receptor (ADORA2B) and improved bone healing. Although further work is needed to extend the findings to human patients, this study provides evidence that the unique functional properties of adenosine along with its local delivery could provide an innovative, safe, and translatable therapeutic strategy to treat bone trauma and associated pain. One Sentence SummaryAdenosine as a therapeutic for fracture pain and healing

bioengineering↗

bioRxiv2019

Integrative modelling of the full-length human dehydrodolichyl diphosphate synthase using a hybrid computational and experimental approach

Dehydrodolichyl diphosphate synthase (DHDDS) and Nogo-B receptor (NgBR) form the heteromeric human cis-prenyltransferase complex, synthesizing the precursor for the glycosyl carrier involved in N-linked protein glycosylation. In line with the important role of N-glycosylation in protein biogenesis, mutations in DHDDS, the catalytic subunit of the complex, were shown to result in human diseases. Importantly, well-characterized DHDDS homologs function as homodimers and not as heteromeric complexes. Moreover, DHDDS encompasses a C-terminal region, which does not converge with any known conserved domains. Therefore, despite the clinical importance of DHDDS, our understating of its structure-function relations remains poor. Here, we provide a structural model for the full-length human DHDDS using a multidisciplinary experimental and computational approach. Our model suggests that the C-terminal domain of DHDDS forms a helix-loop-helix motif, tightly packed against the core catalytic cis-prenyltransferase domain. This model is consistent with small-angle X-ray scattering data, indicating that the full-length DHDDS maintains a similar conformation in solution. Moreover, hydrogen-deuterium exchange mass-spectrometry experiments show time-dependent deuterium uptake in the C-terminal domain, consistent with its overall folded state. Finally, we provide a model for the DHDDS-NgBR heterodimer, offering a structural framework for future structural and functional studies of the human cis-prenyltransferase complex.

biophysics↗